Across TCGA pan-cancer cohorts, SYNJ2BP mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SYNJ2BP’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SYNJ2BP mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SYNJ2BP is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where SYNJ2BP tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SYNJ2BP mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−0.459	<.001	9	view →
HNSC	All	IV	+0.399	<.001	8	view →
LSCC	All	All	−0.247	.001	3	view →
LUAD	Male	All	+0.224	.007	2	view →
COAD	All	All	−0.134	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SYNJ2BP RNA expression & survival · all SYNJ2BP data types